Gesynta Pharma completes enrollment in Phase 2 NOVA trial evaluating vipoglanstat in endometriosis
- Enrollment completed three months ahead of schedule
- NOVA is evaluating vipoglanstat, a novel, non-hormonal, non-opioid drug candidate for the treatment of endometriosis
- Topline data anticipated in Q2 2027
STOCKHOLM, SWEDEN – October 20, 2026 – Gesynta Pharma AB, a clinical-stage biotech company developing vipoglanstat, a non-hormonal, non-opioid therapy that could transform the standard of care for women with endometriosis, today announced that it has completed enrollment in NOVA*, its Phase 2 clinical proof-of-concept and dose-finding trial. With 213 patients randomized against the original target of 190, the trial reached full enrollment more than three months ahead of schedule.
